College of Public Health, University of South Florida, Tampa, Florida, USA.
Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Expert Rev Med Devices. 2021 Nov;18(11):1049-1055. doi: 10.1080/17434440.2021.1992274. Epub 2021 Oct 18.
CGM is an evidence-based intervention to improve glycemic control in persons with T1D and T2D using insulin. Use of CGM in persons with T2D not using insulin is not well studied.
Existing clinical evidence for the use of CGM in persons with T2D is reviewed with a focus on persons with T2D not using insulin. Additional perspective and consideration are provided on the role and rationale for using CGM in persons with T2D not using insulin.
On the basis of available evidence, persons with T2D not using insulin benefit clinically through reduction in HbA1c, and improvement in time in range. Additional benefits include improvement in behavior modification, satisfaction, quality of life, empowerment, and diabetes distress. Drivers of these benefits are independent of insulin use in persons with T2D and may include an improved understanding of how diet, lifestyle, and exercise impact diabetes through CGM use. Clinical benefits from CGM independent of medication use include ability to modify health behavior and subsequently improve self-management.
CGM 是一种基于证据的干预措施，可通过胰岛素改善 1 型和 2 型糖尿病患者的血糖控制。CGM 在未使用胰岛素的 2 型糖尿病患者中的使用尚未得到充分研究。
本文回顾了 CGM 在 2 型糖尿病患者（重点为未使用胰岛素的患者）中的现有临床应用证据，并就 CGM 在未使用胰岛素的 2 型糖尿病患者中的作用和原理提供了额外的观点和考虑。
根据现有证据，未使用胰岛素的 2 型糖尿病患者通过降低 HbA1c 和改善达标时间，在临床上获益。其他获益包括改善行为改变、满意度、生活质量、赋权和糖尿病困扰。这些获益的驱动因素与 2 型糖尿病患者是否使用胰岛素无关，可能包括通过 CGM 使用更好地了解饮食、生活方式和运动对糖尿病的影响。CGM 独立于药物使用带来的临床获益包括能够改变健康行为，从而改善自我管理。
